Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. GLPGCP Development (Asia) Pte. Ltd.
483
•GLPGCP Development (Asia) Pte. Ltd.•January 30, 2026

FDA 483 - GLPGCP Development (Asia) Pte. Ltd. - January 30, 2026

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

An FDA inspection of GLPGCP Development (Asia) Pte. Ltd. in Singapore identified two objectionable conditions related to bioanalytical activities and method validation. The firm failed to consistently follow standard operating procedures for documenting system suitability sample failures and inaccurately recorded method validation activities in source records.

Company
GLPGCP Development (Asia) Pte. Ltd.
Inspection Date
January 30, 2026
Product Type
Biologics
Office
Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
Person
  • Ruben C. Ayala (investigator)
Open in Dashboard

ID · 3a2a3d7b-ae6a-487c-9a90-0d731754259a

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
KeyPedia™ Lite
Legal & Ethics
©2026, Global Key Solutions All rights reserved.